جستجوی استاد راهنمای دانشگاهی

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +۴ مورد دیگر

Karan S Dixit, MD is an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in neuro-oncology and serving as Fellowship Director for the education program. His educational background includes: MD from Louisiana State University (2011) Internal Medicine Internship at University of Illinois at Chicago (2012) Neurology Residency and Chief Medical Resident at University of Illinois at Chicago (2015) Neuro-Oncology Fellowship at Northwestern University McGaw Medical Center (2016) He maintains board certification in Neurology (American Board of Psychiatry and Neurology) and Neuro-Oncology (United Council for Neurologic Subspecialties). Dr. Dixit's research centers on CNS lymphoma, lower-grade gliomas, and glioblastoma, with emphasis on novel therapies for treatment resistance. He investigates biomarkers for disease monitoring and explores neurocognitive decline mechanisms related to neural connectivity changes during CNS cancer treatment. His work bridges clinical neurology with translational oncology through molecular diagnostics and therapeutic innovation. His 2025 publications reveal three critical research trajectories: molecular characterization of glioma mutations (TERT/IDH), liquid biopsy applications for CNS lymphoma diagnosis, and repurposing antiseizure drugs with antineoplastic potential. These studies collectively advance precision medicine approaches for treatment-resistant CNS malignancies. Professional recognition includes: John A Kessler Teaching Award (2022, 2019) NeuroNEXT Fellow (2020) Society of Neuro-Oncology Clinical Trials Course (2019) University of Illinois Teaching Excellence Awards (2014-2015) As Fellowship Director, Dr. Dixit mentors neuro-oncology trainees while leading three active clinical trials: Vorasidenib/Pembrolizumab for IDH-mutant glioma (NCT05484622), NX-5948 BTK degrader for CNS lymphoma (NCT05131022), and emavusertib for relapsed PCNSL (NCT03328078). His industry collaborations include Bluprint Oncology Concepts and Servier Pharmaceuticals for therapeutic development. He maintains active membership in the Feinberg Academy of Medical Educators, American Neurological Association, American Academy of Neurology (Neuro-Oncology Section), American Society of Clinical Oncology, and Society of Neuro-Oncology, collaborating through Northwestern Medicine's Robert H. Lurie Comprehensive Cancer Center and Clinical and Translational Sciences Institute.

• Neuro-Oncology
• Brain Tumors
• Glioblastoma
• +۴ مورد دیگر

Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.

• Cancer Research
• Immunology
• Oncology
• +۳ مورد دیگر

Ari Ristimäki is a Professor in the Department of Pathology at the Clinicum, University of Helsinki, specializing in gastrointestinal tumorigenesis. He serves as a Supervisor in the Doctoral Programme in Biomedicine and maintains strong connections with HUS Radiology and Pathology. His research spans fundamental cancer biology to clinical applications, particularly in colorectal cancer and related gastrointestinal malignancies. Professor Ristimäki's research interests focus on gastrointestinal tumorigenesis, with particular emphasis on colorectal cancer mechanisms, molecular pathways, and clinical applications. His work bridges basic science and clinical practice, investigating the molecular underpinnings of gastrointestinal cancers while developing diagnostic and therapeutic approaches. His research portfolio includes studies on tumor biomarkers, cancer metabolism, epigenetic modifications, and translational applications for improved cancer diagnosis and treatment. His recent publications demonstrate a strong focus on colorectal cancer research, with particular attention to molecular characterization of BRAF-mutated tumors, liquid biopsy technologies for mutation profiling, and population-based studies of surgical outcomes in gastrointestinal cancer patients. His work shows consistent productivity with 311 publications to date, reflecting sustained research activity since the early 2000s. Professor Ristimäki has supervised doctoral theses, serving as both supervisor and opponent for PhD candidates. His academic service includes manuscript reviewing, committee memberships, and editorial work. His current research is supported by multiple active projects from prestigious funding bodies including the Academy of Finland (SA_2024-2028), Sigrid Jusélius Foundation, Cancer Foundation, and Liv och Hälsa Foundation, indicating strong recognition of his research program's significance and potential impact.

• Cancer Research
• Gastrointestinal Tumorigenesis
• Colorectal Cancer
• +۳ مورد دیگر

Steven A. Soper is a Foundation Distinguished Professor in the Department of Chemistry and Mechanical Engineering at the University of Kansas. He serves as Director of the NIH-funded Center for BioModular Multi-Scale Systems for Precision Medicine and leads international collaborations with institutions like UNIST in South Korea. His career spans faculty roles at LSU, UNC, and KU, with interdisciplinary research bridging chemistry, biomedical engineering, and materials science. Ph.D. in Bioanalytical Chemistry, University of Kansas (1989) Postdoctoral Fellow, Los Alamos National Laboratory (1991) B.S. in Chemistry and Psychology, University of Nebraska (1980-1982) Research Interests focus on micro-/nanofabricated biochemical analysis systems for clinical diagnostics, particularly circulating tumor cell analysis , cell-free DNA detection , and single-molecule fluorescence applications. His work integrates polymer microfabrication, FRET-based assays, and thermoplastic nanofluidics for cancer, stroke, and infectious disease diagnostics. Scientific Awards include: R&D 100 Award (2010) Shannon Award (NIH) (1994) Distinguished Research Master, LSU (2002) Fellow, AAAS/RSC/SAS (2010) Sutton Family Research Impact Award (2021) Teaching & Collaboration involves mentoring 39 professional-degree recipients, organizing multidisciplinary research teams, and co-teaching courses in Biofluid Mechanics and Nanotechnology . His lab partners with institutions in South Korea and UNC/NCSU, while hosting international students and professionals. Labs & Centers : Leads the Soper Research Group and the Center for BioModular Multi-Scale Systems , which provides access to state-of-the-art nanofabrication tools and collaborative expertise across 12 institutions.

• Bioanalytical Chemistry
• Microfluidics
• Nanofluidics
• +۷ مورد دیگر

Anthony Lucci, M.D. is a Professor in the Department of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center with a dual appointment in the Department of Surgical Oncology, Division of Surgery. He serves as Principal Investigator of the Lucci Laboratory, focusing on innovative cancer research approaches. Dr. Lucci's research interests center on liquid biopsy-based approaches for cancer detection and monitoring. His laboratory investigates circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), proteomics, and exosomes to develop comprehensive disease snapshots for individual cancer patients. The lab has collected serial blood draws from over 830 breast cancer patients and more than 800 melanoma patients. Specializes in triple-negative and inflammatory breast cancer research Investigates Stage II-IV cutaneous and uveal melanoma Develops methods to predict cancer recurrence Identifies novel therapeutic targets through liquid biopsies Studies mechanisms of treatment resistance The Lucci Laboratory has made significant contributions to understanding how CTCs and ctDNA can predict disease progression better than many conventional clinical parameters. Their research has shown that protein expression in CTCs (like HER2) can differ from primary tumors, opening new therapeutic possibilities for patients.

• Breast Cancer Research
• Triple-negative Breast Cancer
• Inflammatory Breast Cancer
• +۷ مورد دیگر

Amy Catherine Rowat is a full Professor in the Department of Integrative Biology and Physiology at UCLA's College of Letters and Science. She directs an interdisciplinary research program that integrates mechanobiology, microfluidics, cancer biophysics and food engineering to understand how physical forces shape cell behavior and to develop sustainable biotechnologies. Education & Affiliations: Professor, Department of Integrative Biology and Physiology, UCLA Member, UCLA College of Letters and Science Research Interests: Rowat's group deciphers how mechanical properties of cells and their nuclei influence disease progression and therapeutic response. Using high-throughput microfluidic deformability cytometry, her team discovered that cancer cells become stiffer and more invasive upon β-adrenergic signaling, linking stress hormones to metastatic potential. Parallel efforts focus on nuclear envelope mechanics, showing that histone H1.0 and transient nuclear deformation modulate chromatin structure and cell reprogramming. Beyond biomedicine, Rowat pioneers biophysical approaches for sustainable food production. She engineers edible scaffolds and emulsion-templated microcarriers to culture meat at scale, demonstrating spontaneous fusion of adipogenic and myogenic microtissues into marbled steak-like constructs. Recent Article Trends (2020-2025): Her latest publications reveal a cohesive trajectory: coupling mechanobiology to epigenetic regulation (viscoelastic matrix enhances chromatin remodeling), advancing single-cell mechanical phenotyping (optomagnetic arrays, high-throughput screens), translating findings to cancer therapy (β-blockers to sensitize chemotherapy) and expanding engineered foods (scalable cultured-meat bioprocessing). Funding & Awards: NIH R21 CA245667 (PI) – Repurposing beta-blockers to improve chemotherapy response (2021-2023) Laboratory & Teams: Rowat leads an active research laboratory at UCLA that trains graduate students and postdocs at the intersection of physics, engineering and biology. The lab maintains collaborations across UCLA Engineering, Jonsson Comprehensive Cancer Center, and external partners in food science and biotechnology companies.

• Mechanobiology
• Cancer biophysics
• Single-cell mechanics
• +۶ مورد دیگر

Tobias Sjöblom serves as Professor and Head of Department at Uppsala University's Department of Immunology, Genetics and Pathology, where he leads the Cancer Precision Medicine research program. His work bridges clinical oncology and molecular biology, with particular focus on translating genomic findings into clinical applications for cancer patients. His research interests center on cancer genomics, precision medicine, and molecular diagnostics, with extensive work on colorectal cancer biology and treatment. Sjöblom's laboratory investigates how genetic variations influence cancer development, progression, and response to therapy, particularly focusing on pharmacogenomic biomarkers that can guide personalized treatment decisions. His work spans from basic molecular mechanisms to clinical applications, with strong emphasis on translating research findings into clinical practice. Analyzing his recent publication record reveals a clear trajectory toward precision oncology applications, with increasing focus on liquid biopsy technologies, AI-assisted diagnostics, and biomarker-driven treatment strategies. His research demonstrates a consistent pattern of investigating how specific genetic alterations (particularly in NAT2, CYP2D6, and other metabolic enzymes) can be leveraged for targeted cancer therapies. The interdisciplinary nature of his work is evident in collaborations spanning molecular biology, clinical oncology, bioinformatics, and medical imaging. Sjöblom has established significant research infrastructure through initiatives like the U-CAN biobank, creating valuable resources for cancer research across Sweden. His leadership extends to developing novel methodologies for cancer genomics and diagnostics, including advanced techniques for mutation detection and tissue analysis. His laboratory maintains strong clinical connections, working closely with oncologists and surgeons to ensure research questions address real clinical challenges. This translational approach has resulted in numerous publications in high-impact journals including Nature, Science, and Cell Death and Disease, demonstrating the significance and quality of his contributions to cancer research.

• Cancer Genomics
• Precision Medicine
• Colorectal Cancer Research
• +۵ مورد دیگر

A.T. Charlie Johnson serves as the Rebecca W. Bushnell Professor of Physics and Astronomy at the University of Pennsylvania's School of Arts & Sciences, where he has been a standing faculty member since 1994. His research program focuses on nanoscale systems and has established him as a leading figure in condensed matter physics, earning recognition from major scientific societies. His educational foundation includes: Ph.D. in Physics from Harvard University (1990) B.S. in Physics from Stanford University (1984) Professor Johnson's research centers on the development and application of atomic-layer nanomaterials, particularly graphene and transition metal dichalcogenides , for fundamental studies of transport phenomena and practical biosensor applications. His group employs advanced nanofabrication techniques at Penn's Singh Center for Nanotechnology to create devices that leverage biological molecules for chemical recognition in disease diagnosis, security screening, and environmental monitoring. This work bridges condensed matter physics with biomedical engineering , yielding innovative solutions for real-world detection challenges. Analysis of his 2023-2025 publications reveals three dominant research thrusts: (1) scalable graphene-based biosensor development for medical diagnostics, (2) exploration of quantum phenomena like Klein tunneling in novel nanoelectromechanical systems, and (3) interdisciplinary applications spanning oncology, planetary science, and fetal medicine. His work consistently emphasizes materials synthesis , device integration , and practical translation of nanoscale phenomena. His scientific contributions have been recognized with prestigious honors: Defense Science Study Group Fellow (2018-2019) Fellow of the American Association for the Advancement of Science (2017) Fellow of the American Physical Society (2011) Lindback Foundation Award for Distinguished Teaching (2003) David and Lucille Packard Foundation Fellowship (1994-1999) As an educator, Professor Johnson has mentored numerous graduate students and postdoctoral researchers, with notable alumni like Michael Biercuk (founder of Q-CTRL). His research has been supported through significant leadership roles including Director of the Nano/Bio Interface Center (2014-2017) and Packard Fellowship funding, enabling sustained innovation in nanotechnology. His group actively collaborates across disciplines to advance both fundamental understanding and practical applications of nanomaterials. Based at the Singh Center for Nanotechnology, Johnson leads a dynamic research team utilizing state-of-the-art facilities for nanofabrication and characterization. His laboratory maintains strong campus collaborations through secondary appointments in Electrical and Systems Engineering and Materials Science and Engineering, fostering an interdisciplinary environment for developing next-generation nanoscale devices.

• Condensed Matter Physics
• Nanotechnology
• Nanomaterials
• +۴ مورد دیگر

Dr. Charlotte Kuperwasser is a distinguished Professor in the Department of Developmental, Molecular, and Chemical Biology at Tufts University School of Medicine . She directs the Tufts Convergence Laboratory and focuses on molecular mechanisms governing breast tissue development, cancer prevention, and organoid technologies. Her work integrates stem cell biology, epigenetics, and environmental influences such as endocrine disruptors. Education: Bachelor of Science (1997), University of Massachusetts Amherst PhD (2000), University of Massachusetts Amherst Jane Coffin Childs Postdoctoral Fellow (MIT/Whitehead Institute) Research Interests: Her lab develops 3D breast organoid models to study cancer initiation, microenvironmental interactions, and BRCA1-related mechanisms. Recent efforts include analyzing HPV-driven cancers via circulating tumor DNA and studying fibroblast signaling (e.g., DDR1) in tumor progression. Grants & Awards: Howard Hughes Fellowship, Merck Fellowship COG/Aventis Young Investigator Award Natalie V. Zucker Award NIH grants on V-ATPases and obesity-cancer links Professional Contributions: She chairs Tufts’ Sackler Convergence Laboratory and serves on AACR committees. Teaching includes courses on Molecular Cell Biology of Development and Cancer Genetics . Labs/Teams: Leads the Kuperwasser Lab, focusing on translational cancer research with cross-disciplinary collaborations in organoid engineering and clinical diagnostics.

• Breast Cancer Research
• Mammary Gland Biology
• Cancer Prevention
• +۴ مورد دیگر

Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.

• Neurosurgery
• Neuro-oncology
• Molecular Neurobiology
• +۵ مورد دیگر

Ash A. Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, where he serves as leader of the Cancer Genomics Program at Stanford Cancer Institute. He holds multiple academic appointments including Professor in Medicine - Oncology, and membership in Bio-X, the Institute for Stem Cell Biology and Regenerative Medicine, and the Maternal & Child Health Research Institute (MCHRI). Dr. Alizadeh received his BS in Biochemistry from UCLA (1994), MD from Stanford Medical School, and PhD in Biophysics from Stanford. He completed additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). His primary research focuses on developing and applying genome technologies and computing (machine learning & data science) to problems in human disease, with special emphasis on cancer detection, classification, monitoring, and tumor immunology. His laboratory pioneers noninvasive cancer genomic techniques including CAPP-Seq, PhasED-Seq, and EPIC-Seq for "liquid biopsies" that analyze circulating nucleic acids for early cancer detection and monitoring therapeutic response. Using machine learning approaches, his group studies how cellular compositional variation impacts cancer behavior and therapeutic response, including anti-tumor immunity. His work spans molecular, cellular, organism and population levels of tumor behavior analysis. Dr. Alizadeh has received numerous prestigious awards including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, and Doris Duke Charitable Research Foundation. He is an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Scientific Advisory Board of the Lymphoma Research Foundation (LRF). As an educator and mentor, Dr. Alizadeh advises numerous doctoral students, postdoctoral fellows, and medical scholars. He teaches in the Department of Medicine and Immunology and serves on various admissions panels at Stanford. His laboratory, the Alizadeh Lab, is a hub for interdisciplinary cancer genomics research that combines computational biology, molecular genetics, and clinical oncology to develop novel cancer diagnostics and therapeutics.

• Cancer Genomics
• Liquid Biopsies
• Machine Learning in Oncology
• +۷ مورد دیگر

J. Christopher Love is the Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering at MIT, with affiliations to the Koch Institute for Integrative Cancer Research, Broad Institute, and Ragon Institute. He earned a BS in Chemistry from the University of Virginia and a PhD in Physical Chemistry from Harvard University under George Whitesides, followed by postdoctoral work under Hidde Ploegh at Harvard Medical School. His research focuses on single-cell analysis, precision medicine, and biomanufacturing. The Love Lab develops technologies for drug discovery, vaccine development, and equitable biologic medicine production. Notable successes include pioneering single-cell analysis platforms, advancing metastatic cancer diagnostics via liquid biopsies, and engineering yeast-based vaccine manufacturing. Recent articles highlight innovations in liquid biopsy sensitivity, AI-driven ECG diagnostics, and CAR T-cell therapies. Awards include the Keck Young Scholar (2009), Dana Scholar (2009), and Camille Dreyfus Teacher-Scholar. He co-founded OneCyte, HoneyComb, and Sunflower Therapeutics, and advises multiple biotech companies. His lab emphasizes translational research, integrating chemical and biological engineering principles to address global healthcare challenges. Current work explores manufacturability-by-design for vaccines, tumor immunology, and mucosal vaccine delivery systems.

• Nano-based drugs
• Precision medicine
• Immunology
• +۳ مورد دیگر

Katherine E. Varley, PhD is a Huntsman Cancer Institute Investigator and Associate Professor in the Department of Oncological Sciences at the University of Utah. She leads the Varley Lab and is a member of the Nuclear Control of Cell Growth and Differentiation Program, focusing on breast cancer genomics, epigenetics, and biomarker discovery. Her work bridges computational biology with clinical applications to improve breast cancer diagnosis and treatment. Dr. Varley earned her BS in Biology with a concentration in Computational Biology from Cornell University in 2003, followed by a PhD in Computational Biology from Washington University School of Medicine in 2009 under Dr. Robi Mitra. Her postdoctoral training was conducted in Dr. Richard M. Myers' laboratory at the HudsonAlpha Institute for Biotechnology, where she participated in the ENCODE Project Consortium. Her research focuses on using next-generation sequencing and computational analysis to study gene expression, transcription factor binding, and DNA methylation patterns in breast cancer. The Varley Lab investigates epigenetic gene regulation, develops novel molecular methods and bioinformatics approaches, and translates discoveries into clinical tools. Key research areas include Clinical Trial Genomics, Epigenome Engineering, Detecting Circulating Tumor DNA, and identifying Transcription Factors Driving Metastasis, with particular emphasis on triple-negative breast cancer. Analysis of Dr. Varley's publications reveals a consistent trajectory from fundamental genomic mechanisms to clinical translation, with recent work emphasizing biomarker discovery, tumor heterogeneity, and the development of genomic tools for precision oncology. Her research spans cancer biology, genomics, and computational analysis to address critical challenges in breast cancer treatment. Dr. Varley holds multiple patents related to cancer diagnostics and genomic technologies, including targeted sequencing methods, multigene assays for recurrence risk, and biomarkers for triple-negative breast cancer. These inventions reflect her commitment to translating basic research into clinical applications. She actively collaborates with clinical investigators in breast cancer trials and works closely with the Breast and Gynecologic Cancers Disease Center at Huntsman Cancer Institute. Her lab maintains four main research thrusts that collectively address breast cancer from molecular mechanisms to clinical applications, demonstrating a comprehensive approach to improving patient outcomes through genomic technologies.

• Breast Cancer
• Epigenetics
• Gene Expression Regulation
• +۵ مورد دیگر

Sampsa Hautaniemi is a Professor at the Department of Biochemistry and Developmental Biology within the Faculty of Medicine at the University of Helsinki. He serves as Principal Investigator of the Systems Biology of Drug Resistance in Cancer research group and holds docentship in the Faculty of Medicine. Professor Hautaniemi actively supervises doctoral students across multiple programs including the Doctoral Programme in Biomedicine, Doctoral Programme in Clinical Research, and Doctoral Programme in Integrative Life Science. His research focuses on systems biology approaches to understand drug resistance mechanisms in cancer, particularly ovarian cancer. His work integrates computational biology, genomics, epigenetics, and bioinformatics to develop precision medicine approaches for cancer treatment. His laboratory develops innovative computational methods and experimental models including patient-derived organoids to study tumor evolution, identify therapeutic targets, and predict treatment responses. Analysis of his recent publications reveals a strong emphasis on understanding tumor heterogeneity, clonal evolution during therapy, and the development of computational tools for cancer genomics. His work spans multiple disciplines including cancer biology, computational biology, immunology, and precision medicine, with a particular focus on high-grade serous ovarian cancer as a model system. Scientific Awards: The Anders Jahre Medical Prize to young medical scientists (2014) for outstanding research on systems biology and cancer The Finnish Medical Foundation 50-years jubileum award (2010) Professor Hautaniemi has supervised numerous doctoral students and early-career researchers, contributing significantly to cancer research education. His research is supported by multiple active projects including the DECIDER project (Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer) funded until 2026, as well as projects from the Academy of Finland, Cancer Foundation, and industry partners like Orion Corporation. His laboratory maintains a patient-derived organoid biobank for high-grade serous ovarian cancer and develops computational tools like Jellyfish for visualizing tumor evolution.

• Systems Biology
• Cancer Research
• Drug Resistance
• +۷ مورد دیگر